When the Senate Judiciary Committee convened on May 21 for a hearing on Competition in the Prescription Drug Market, Senators were besieged with an array of tired and superficial arguments against patents for biopharmaceutical innovation. The main premise seemed to be that holding more than a single patent for a single product must be anti-competitive. These arguments fly in the face of technological, economic, and legal reality, where patents cover inventions and discoveries rather than products. The ubiquitous mobile phone by one estimate contains 250,000 patented inventions, each adding a unique capability or solving a technical problem, which collectively enable the whole phone to work as intended.
Recent Posts
- Stewart Says USPTO Wants Early Validity Challenges, Not Late IPRs
- Solutions for a Better Patent System | IPWatchdog Unleashed
- The Impact of Price Controls and Biologics on the Future of U.S. Pharmaceutical Innovation and Investment
- Other Barks & Bites for Friday, June 6: UK House of Lords Insists on Copyright Transparency in AI Bill; OpenAI Vows to Appeal New York Times Ruling; and Stewart Sua Sponte Orders Review of PTAB Win for TikTok
- Squires’ Responses to Senate Judiciary Committee Focus on Balance, Backlog and ‘Born Strong’ Patents